Designed to optimize glucose management, the minimally invasive system displays patient’s interstitial glucose value in real time and provides predictive alarms to facilitate clinicians to intervene and prevent glycemic excursions.
The monitor, which features a subcutaneous sensor, uses Redundant sensing technology for visibility of glycemic variability.
In addition, the system includes a drug interference rejection technology that ensures minimal interference with various pharmaceuticals used in the CCU, as well as a configurable system that integrates into clinical workflow to improve the efficiency of maintaining glucose control.
Academisch Medisch Centrum intensive care medicine department Professor M.J. Schultz said, "Introduction of the CGM technology in critically ill patients is a high priority that will help improve our insight in insulin resistance, will increase understanding of the effects of glycemic variability and will facilitate any blood glucose control strategy."
Sentrino is an investigational device and is not available for sale in the US.
Medtronic continuous glucose monitoring business vice president and general manager Greg Meehan said, "Given the market need for CGM in CCU patients, we believe the market potential will exceed $1 billion globally."
